ES2555785T3 - Remedio o preventivo para esquizofrenia - Google Patents

Remedio o preventivo para esquizofrenia Download PDF

Info

Publication number
ES2555785T3
ES2555785T3 ES08777453.5T ES08777453T ES2555785T3 ES 2555785 T3 ES2555785 T3 ES 2555785T3 ES 08777453 T ES08777453 T ES 08777453T ES 2555785 T3 ES2555785 T3 ES 2555785T3
Authority
ES
Spain
Prior art keywords
schizophrenia
line
remedy
preventive
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08777453.5T
Other languages
English (en)
Inventor
Satoru Yoshikawa
Hidenori Mochizuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2555785T3 publication Critical patent/ES2555785T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Agente terapéutico o profiláctico para su utilización en el tratamiento de la esquizofrenia, que comprende, como ingrediente eficaz, un compuesto representado mediante la fórmula general (I) a continuación:**Fórmula** en la que la línea doble, constituida por una línea de puntos y una línea continua, representa un doble enlace o un enlace sencillo, R1 representa cicloalquilalquilo C4-C7, R2 representa alquilo C1-C5 lineal o ramificado y B representa -CH>=CH-, o una sal de adición de ácido farmacéuticamente aceptable del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES08777453.5T 2007-06-22 2008-06-20 Remedio o preventivo para esquizofrenia Active ES2555785T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007164868 2007-06-22
JP2007164868 2007-06-22
PCT/JP2008/061309 WO2009001764A1 (ja) 2007-06-22 2008-06-20 統合失調症の治療または予防剤

Publications (1)

Publication Number Publication Date
ES2555785T3 true ES2555785T3 (es) 2016-01-08

Family

ID=40185582

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08777453.5T Active ES2555785T3 (es) 2007-06-22 2008-06-20 Remedio o preventivo para esquizofrenia

Country Status (11)

Country Link
US (1) US8183256B2 (es)
EP (1) EP2168580B1 (es)
JP (1) JP5343848B2 (es)
KR (1) KR101492029B1 (es)
CN (1) CN101778632B (es)
AU (1) AU2008268202B2 (es)
CA (1) CA2691220C (es)
ES (1) ES2555785T3 (es)
MX (1) MX2009014181A (es)
PL (1) PL2168580T3 (es)
WO (1) WO2009001764A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173491A (en) 2010-01-29 2020-01-29 Toray Industries Therapeutic or prophylactic agent for biliary tract diseases
JP5929753B2 (ja) 2011-01-31 2016-06-08 東レ株式会社 悪液質の治療又は予防剤
TWI449704B (zh) * 2013-04-26 2014-08-21 Everlight Chem Ind Corp 嗎啡喃衍生物之結晶、其製造方法、及使用其之醫藥組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01149788A (ja) 1987-12-08 1989-06-12 Chugai Pharmaceut Co Ltd 新規なモルヒネ誘導体
NZ246687A (en) * 1992-01-23 1996-12-20 Toray Industries Morphinan derivative and pharmaceutical compositions thereof
CN1111900A (zh) * 1993-06-30 1995-11-15 东丽株式会社 止咳药
KR100341950B1 (ko) 1993-07-19 2002-11-29 도레이 가부시끼가이샤 뇌세포보호제
ATE263563T1 (de) * 1996-11-25 2004-04-15 Toray Industries Mittel gegen juckreiz
AU6117298A (en) 1997-07-25 1999-02-16 Toray Industries, Inc. Hyponatremia remedies
JPH1192376A (ja) * 1997-09-17 1999-04-06 Toray Ind Inc ニコチン依存症治療剤
EP0974363B1 (en) * 1997-09-02 2005-06-22 Toray Industries, Inc. Remedies for drug addiction
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
US6476208B1 (en) * 1998-10-13 2002-11-05 Genset Schizophrenia associated genes, proteins and biallelic markers
JP2000169476A (ja) * 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
CA2383146C (en) 1999-08-24 2010-11-16 Hiroshi Nagase Therapeutic agent for neuropathic pain and neuropathic pain animal model
PT1380306E (pt) 2001-03-30 2009-05-25 Toray Industries Medicamentos para psiconeurose
EP1402899A4 (en) 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
US7553908B1 (en) * 2003-01-30 2009-06-30 Prc Desoto International, Inc. Preformed compositions in shaped form comprising polymer blends
WO2005085228A1 (ja) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. シクロアルカノピリジン誘導体
JP2005289886A (ja) 2004-03-31 2005-10-20 Satoko Sawaguchi 自傷行動抑制薬
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
EP1870413B1 (en) 2005-03-10 2013-07-10 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis
US7829586B2 (en) 2005-09-30 2010-11-09 Banyu Pharmaceutical Co., Ltd. Aryl-substituted nitrogen-containing heterocyclic compounds
EP2001495A4 (en) * 2006-02-27 2010-12-08 Alexander Michalow METHODS OF REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATION

Also Published As

Publication number Publication date
KR20100023001A (ko) 2010-03-03
CA2691220A1 (en) 2008-12-31
JPWO2009001764A1 (ja) 2010-08-26
CN101778632A (zh) 2010-07-14
CN101778632B (zh) 2012-02-29
US8183256B2 (en) 2012-05-22
PL2168580T3 (pl) 2016-06-30
KR101492029B1 (ko) 2015-02-10
US20100160364A1 (en) 2010-06-24
AU2008268202B2 (en) 2012-12-20
JP5343848B2 (ja) 2013-11-13
CA2691220C (en) 2015-05-05
AU2008268202A1 (en) 2008-12-31
EP2168580B1 (en) 2015-12-02
EP2168580A4 (en) 2011-08-17
MX2009014181A (es) 2010-03-04
WO2009001764A1 (ja) 2008-12-31
EP2168580A1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
DOP2012000011A (es) Formulacion farmaceutica
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
DOP2006000170A (es) Nuevos derivados de espirocromanona
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
CR9230A (es) Uso de derivados del acido tetramico para el control de los insectos del genero de los hemipteros (sternorrhyncha)
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR078142A1 (es) Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos.
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
ES2555785T3 (es) Remedio o preventivo para esquizofrenia
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata